公开(公告)号：AU2012200399A1

公开(公告)日：2012-02-16

申请号：AU2012200399

申请日：2012-01-23

Applicant: ABBOTT LAB

Inventor： ZHU GUIDONG ,  GONG JIANCHUN ,  GANDHI VIRAJKUMAR B ,  GIRANDA VINCENT ,  PENNING THOMAS D

IPC: C07D401/04 ,  A61K31/4184 ,  A61K31/454 ,  A61K31/55 ,  A61P9/10 ,  C07D403/04

Abstract: 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP Abstract 5 Compounds of Formula (I) (I) inhibit the PARP enzyme and are useful for treating a disease or a disorder associated to with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of treatment comprising compounds of Formula (I), and methods of inhibiting the PARP enzyme comprising compounds of Formula (I).

公开(公告)号：BRPI0707902A2

公开(公告)日：2011-05-17

申请号：BRPI0707902

申请日：2007-02-15

Applicant: ABBOTT LAB

Inventor： PENNING THOMAS D ,  ZHU GUI-DONG ,  GANDHI VIRAJKUMAR B ,  GONG JIANCHUN ,  GIRANDA VICENT L

IPC: C07D471/04 ,  A61K31/438 ,  A61P35/00 ,  C07D491/04 ,  C07D495/04

Abstract: Compounds of Formula (I) inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of treatment comprising compounds of Formula (I), and methods of inhibiting the PARP enzyme comprising compounds of Formula (I).

公开(公告)号：CA2767091A1

公开(公告)日：2011-01-20

申请号：CA2767091

申请日：2010-07-14

Applicant: ABBOTT LAB

Inventor： PENNING THOMAS D ,  GANDHI VIRAJ B ,  ZHU GUIDONG ,  TONG YUNSONG ,  WOODS KEITH W ,  LAI CHUNQIU ,  GONG JANE ,  FLORJANCIC ALAN S

IPC: C07D487/04 ,  A61P35/00

Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1a, R1b, X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.

公开(公告)号：ES2342007T3

公开(公告)日：2010-06-30

申请号：ES06837694

申请日：2006-11-15

Applicant: ABBOTT LAB

Inventor： PENNING THOMAS D ,  THOMAS SHEELA A ,  ZHU GUI-DONG ,  GONG JIANCHUN ,  GIRANDA VINCENT L ,  GANDHI VIRAJ B

IPC: C07D235/18

Abstract: Un compuesto de Fórmula (I) **(Ver fórmula)** o una de sus sales terapéuticamente aceptables, donde R1, R2, y R3 se seleccionan independientemente del grupo que consiste en hidrógeno, alquenilo C2-C10, alcoxi C1-C10, (alcoxi C1-C10)carbonilo, alquilo C1-C10, alquinilo C1-C10, ciano, haloalcoxi C1-C10, haloalquilo C1-C10, halógeno, hidroxi, hidroxialquilo C1-C10, nitro, NRARB, y (NRARB)carbonilo; X1 es fenilo, donde X1 está sustituido opcionalmente con 1, 2, 3, o 4 sustituyentes seleccionados del grupo que consiste en alquilo C1-C10, ciano, halógeno, y haloalquilo C1-C10; W es X2-Y-NR6R7 o Y-NR6R7; X2 se selecciona del grupo que consiste en arilo y heteroarilo, donde arilo es fenilo o naftilo, y donde heteroarilo es benzotienilo, benzoxadiazolilo, cinolinilo, furopiridinilo, furilo, imidazolilo, indazolilo, indolilo, isoxazolilo, isoquinolinilo, isotiazolilo, naftiridinilo, oxadiazolilo, oxazolilo, piridinilo, piridazinilo, pirimidinilo, pirazinilo, pirazolilo, pirrolilo, N-oxido de piridinio, quinolinilo, tetrazolilo, tiadiazolilo, tiazolilo, tienopiridinilo, tienilo, triazolilo, o triazinilo, donde X2 está sustituido opcionalmente con 1, 2, 3, o 4 sustituyentes seleccionados del grupo que consiste en alquilo C1-C10, ciano, halógeno, y haloalquilo C1-C10; Y es alquilenilo C1-C6; R6 se selecciona del grupo que consiste en hidrógeno, alquenilo C2-C10, alcoxi C1-C10-alquilo C1-C10, (alcoxi C1-C10)carbonilo, (alcoxi C1-C10)carbonil-alquilo C1-C10, alquilo C1-C10, alquinilo C1-C10,, fenilo, naftilo, cicloalquilo C3-C8, cicloalquil C3-C8-alquilo C1-C10, y hidroxialquilo C1-C10; R7 se selecciona del grupo que consiste en cicloalquilo C3-C8 y cicloalquilo C3-C8 fusionado a fenilo, donde R7 puede estar sustituido opcionalmente con 1, 2, o 3 sustituyentes seleccionados del grupo que consiste en alquenilo C2-C10, alcoxi C1-C10, alcoxi C1-C10-alquilo C1-C10, (alcoxi C1-C10)carbonilo, (alcoxi C1-C10)carbonil-alquilo C1-C10, alquilo C1-C10, (alquil C1-C10)carbonilo, (alquil C1-C10)carbonil-alquilo C1-C10, alquinilo C1-C10, carboxi, cicloalquilo C3-C8, cicloalquil C3-C8-alquilo C1-C10, ciano, haloalcoxi C1-C10, haloalquilo C1-C10, halógeno, hidroxi, hidroxialquilo C1-C10, NRCRD; (NRCRD)-alquilo C1-C10, (NRCRD)carbonilo, (NRCRD)carbonil-alquilo C1-C10, (NRCRD)sulfonilo, y oxo; y RA, RB, RC, y RD se seleccionan independientemente del grupo que consiste en hidrógeno, alquilo C1-C10, y (alquil C1-C10)carbonilo.

公开(公告)号：CA2690761A1

公开(公告)日：2009-01-22

申请号：CA2690761

申请日：2008-07-16

Applicant: ABBOTT LAB

Inventor： GANDHI VIRAJKUMAR B ,  GIRANDA VINCENT L ,  GONG JIANCHUN ,  PENNING THOMAS D ,  ZHU GUI-DONG

IPC: C07D417/14 ,  A61K31/427 ,  A61P35/00 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14

Abstract: Compounds which inhibit the activity of poly(ADP-ribose)polymerase (PARP), compositions containing the compounds and methods of treating diseases using them are disclosed.

公开(公告)号：CA2672868A1

公开(公告)日：2008-07-10

申请号：CA2672868

申请日：2007-12-20

Applicant: ABBOTT LAB

Inventor： PENNING THOMAS D ,  ZHU GUI-DONG ,  GANDHI VIRAJ B ,  GONG JIANCHUN ,  GIRANDA VINCENT L

IPC: A01N43/58 ,  A61K31/495 ,  A61K31/50

Abstract: Inhibitors of poly(ADP-ribose)polymerase, ways to make them and methods o f treating patients using them are disclosed.

公开(公告)号：AU2007340020A1

公开(公告)日：2008-07-10

申请号：AU2007340020

申请日：2007-12-20

Applicant: ABBOTT LAB

Inventor： GONG JIANCHUN ,  GIRANDA VINCENT L ,  GANDHI VIRAJ B ,  ZHU GUI-DONG ,  PENNING THOMAS D

IPC: A01N43/58 ,  A61K31/495 ,  A61K31/50

Abstract: A compound selected from the group consisting of 1-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)pyrrolidine-2,5-dione and 4-(3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one, or a pharmaceutically acceptable salt thereof, for use in treating leukemia, colon cancer, glioblastomas, lymphomas, melanomas, carcinomas of the breast or cervical carcinomas in a mammal by administering thereto a therapeutically acceptable amount of said compound.

公开(公告)号：BRPI0722070A2

公开(公告)日：2014-04-08

申请号：BRPI0722070

申请日：2007-12-20

Applicant: ABBOTT LAB

Inventor： GANDHI VIRAJ B ,  GIRANDA VINCENT L ,  GONG JIANCHUN ,  PENNING THOMAS D ,  ZHU GUI-DONG

IPC: A01N43/58 ,  A61K31/495 ,  A61K31/50

Abstract: A compound selected from the group consisting of 1-(2-fluoro-5-((4-oxo-3,4,5,6,7,8-hexahydrophthalazin-1-yl)methyl)phenyl)pyrrolidine-2,5-dione and 4-(3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl)-5,6,7,8-tetrahydrophthalazin-1(2H)-one, or a pharmaceutically acceptable salt thereof, for use in treating leukemia, colon cancer, glioblastomas, lymphomas, melanomas, carcinomas of the breast or cervical carcinomas in a mammal by administering thereto a therapeutically acceptable amount of said compound.

公开(公告)号：CA2647592C

公开(公告)日：2014-01-28

申请号：CA2647592

申请日：2007-05-24

Applicant: ABBOTT LAB

Inventor： DIEBOLD ROBERT B ,  DJURIC STEVAN W ,  GIRANDA VINCENT L ,  HEXAMER LAURA ,  LIN NAN-HORNG ,  MIYASHIRO JULIE M ,  PENNING THOMAS D ,  PRZYTULINSKA MAGDALENA ,  SOWIN THOMAS ,  SULLIVAN GERARD ,  TAO ZHI-FU ,  TONG YUNSONG ,  VASUDEVAN ANIL ,  WANG LE ,  WOODS KEITH W ,  XIA ZHIREN ,  ZHANG HENRY Q

IPC: C07C225/20 ,  A61K31/132 ,  A61K31/505 ,  A61P35/00 ,  C07D249/14 ,  C07D277/64 ,  C07D285/06 ,  C07D333/20

Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, (see formula I) wherein X1, C1, and D1 are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting Plk1, Plk1 causes mitotic arrest, and inhibitors of Plk1 are cytotoxic agents that are useful for treatment of diseases of cellular proliferation, such as, for example, cancer.

公开(公告)号：ES2426981T3

公开(公告)日：2013-10-28

申请号：ES11189346

申请日：2006-04-11

Applicant: ABBOTT LAB

Inventor： ZHU GUIDONG ,  GONG JIANCHUN ,  GANDHI VIRAJKUMAR B ,  PENNING THOMAS D ,  GIRANDA VINCENT

IPC: A61K31/4184 ,  A61K31/454 ,  A61K31/55 ,  A61P9/10

Abstract: Un compuesto de Fórmula (I),**Fórmula** o una sal terapéuticamente aceptable del mismo, para su uso en el tratamiento de cáncer en un mamífero con unanecesidad reconocida de dicho tratamiento, donde R1, R2, y R3 se seleccionan independientemente entre el grupo que consiste en hidrógeno, alquenilo, alcoxi,alcoxicarbonilo, alquilo, alquinilo, ciano, haloalcoxi, haloalquilo, halógeno, hidroxi, hidroxialquilo, nitro, NRARB y(NRARB)carbonilo; A es R5 se selecciona independientemente entre el grupo que consiste en alquenilo, alcoxi, alcoxicarbonilo, alquilo,alquinilo, haloalcoxi, haloalquilo, halógeno, hidroxi, hidroxialquilo, NRCRD, y (NRCRD)carbonilo; n es 0, 1, 2 o 3; R6 se selecciona entre el grupo que consiste en hidrógeno, alquenilo, alcoxialquilo, alcoxicarbonilo,alcoxicarbonilalquilo, alquilo, alquinilo, arilo, arilalquilo, cicloalquilo, cicloalquilalquilo, heterociclo,heterocicloalquilo, heteroarilo, heteroarilalquilo, hidroxialquilo, (NRCRD)alquilo, (NRCRD)carbonilo,(NRCRD)carbonilalquilo y (NRCRD)sulfonilo; RA y RB se seleccionan independientemente entre el grupo que consiste en hidrógeno, alquilo y alquilcarbonilo; yRC y RD se seleccionan independientemente entre el grupo que consiste en hidrógeno y alquilo.